Members of the Vaccines and Related Biological Products Advisory Committee did not find the promise for a 30,000-patient post-market safety study sufficient to assuage their concerns about the risks of approving Dynavax Technologies Corp.’s hepatitis B vaccine Heplisav (rHBsAg-1018 ISS) for the general adult population.
The panel voted 8 to 5 with one abstention that available data do not support the safety of the vaccine...